Claritev's Turnaround Takes Hold: Q2 2026 Inflection Point
Revenue, bookings, and cash flow all accelerate as NSA and AI drive a sustainable growth story.
CTEV · Earnings Call · 2026-08-07
The Turn Is Real
For a company that spent the past two years battling a single-client headwind, margin compression, and a skeptical market, Claritev's second quarter was a definitive statement. Revenue reached $257.5 million, up 6.6% year-over-year—the fifth consecutive quarter of growth and the highest quarterly revenue since Q3 2022. More importantly, the quality of that growth improved: adjusted EBITDA of $155.8 million was a 13-quarter high, and unlevered free cash flow jumped 24% to $89.5 million. The company is not just recovering; it is compounding. As CFO Doug Garis put it: “Total revenue in the quarter was $257.5 million, up 6.6% year-over-year. This marks the fifth straight quarter of year-over-year revenue growth and was our highest revenue quarter in 15 quarters back to Q3 of '22.” — Doug Garis, Chief Financial Officer · 2026-08-07 The momentum is broad-based. In the Earnings growth category, Claritev is now confident enough to raise full-year guidance: revenue to $1.0–1.02 billion (4–6% growth), adjusted EBITDA to $610–620 million, and free cash flow to $5–15 million. The book of business is expanding faster than internal plans, with ACV bookings of $30 million in Q2 alone, taking the first half to $74 million—more than the $67 million booked for all of 2025. Management's confidence is not abstract; it is backed by a pipeline of $300 million, up 50% year-over-year, and a win rate that continues to improve.NSA and AI: The Growth Engine
The most compelling narrative shift is in the No Surprises Act (NSA) and independent dispute resolution (IDR) space. Claritev has positioned itself as the indispensable scale player in a regulatory environment that keeps getting more complex. The newly finalized IDR rules, which cut the cost per dispute from $115 to $15, have increased operational burdens—but Claritev's automation and IDR process expertise turn that into an advantage. As Travis Dalton explained: “No company has demonstrated a greater ability to manage NSA claims at scale than Claritev. Our arbitration outcomes continue to outperform the industry by approximately 8 percentage points.” — Travis Dalton, President and Chief Executive Officer · 2026-08-07 Behind this is a deliberate AI strategy that has been gestating for years. Claritev's digital transformation—modern cloud architecture, organized data, and deep domain expertise—has made it one of the few health technology firms where AI is not a pilot project but a production lever. “We view artificial intelligence as an accelerator of both growth and operating leverage in an area where Claritev has built a meaningful competitive advantage.” — Travis Dalton, President and Chief Executive Officer · 2026-08-07 The results are tangible: the ProPricer AI product has identified over $1 billion in additional savings, and customer-facing AI now automates provider data validation and ineligibility assessments in the IDR process, cutting both cost and turnaround time. This is a stark contrast to prior quarters. Just two calls ago, in November 2025, Doug Garis was still explaining, “We feel pretty confident that at least 60% to 65% of the ACV we book turns into revenue and converts to revenue next year.” — Doug Garis, Chief Financial Officer · 2025-11-07 Now, the company is already beating that conversion rate and experiencing the upfront revenue benefit of a large NSA win that turned on faster than expected.Diversification and Cash Engine
Claritev is also reducing its concentration risk. The TPA vertical delivered the largest share of bookings this quarter, including several seven-figure deals like Marpai. Medicare Advantage is being seeded as a long-term growth arena, with a newly signed high-six-figure ACV deal. The mix is shifting away from pure payer dependence toward public sector and provider markets—all while the core remains resilient. As Travis noted:The cash flow story is equally important. Operating cash flow hit $93 million in Q2, up 51% year-over-year, and working capital management improved (DPO and DSO each improved by over 5 days). This is the fuel for continued investment—sales, marketing, and technology—without straining the balance sheet. The company reiterated its capital expenditure plan of $160–170 million and expects cash conversion to normalize above 50% by year-end. None of this is boilerplate. Two years ago, the market doubted whether the core business could grow at all after a major client in-sourced its analytics. The turnaround is not just returning to pre-decline levels; it is fundamentally broadening the business model. The commercial readiness is evident in the win rates, the pipeline, and the leadership team's ability to execute. “Our results demonstrate that our strategy is working, our execution is strengthening, growth is returning, and we are building forward momentum across the business.” — Todd Friedman, Head of Investor Relations · 2026-08-07 For investors who have followed the multi-year slog, this is the first quarter where the turn is not just promised but demonstrated. With raised guidance, accelerating cash generation, and a clear AI-driven moat in NSA, Claritev has earned the right to be viewed as a re-rating candidate rather than a distressed recovery story.Our leadership team is fully formed and it's finding its rhythm. Transforming a 45-year-old business is not a small task, but the momentum at Claritev is real, and you can feel it every day.